- Sort by:
- Browse by:
- Free
- audio + slides
- Some slides withheld
Immunity against cancer: How to be enhanced?
Jolanda de Vries
Nijmegen Centre for Molecular Life Sciences, Nijmegen, Netherlands
- Free
- slides video
- audio + slides
- All slides included
Gene-modified T cells as biotherapeutics for cancer
Stephen Gottschalk
Baylor College of Medicine, Houston, TX, United States
- Free
- audio + slides
- Some slides withheld
Immune checkpoint inhibitors: Opportunities and challenges
Mary L. (Nora) Disis
University of Washington, Seattle, WA, United States
- Free
- slides video
- audio + slides
- All slides included
Mutation-driven drug development (targeted agents) vs. immunotherapeutics development
Alexander M Eggermont
Gustave Roussy Cancer Institute, Villejuif, Paris-Sud, France
- Free
- audio + slides
- Some slides withheld
CAR therapy for cancer: Emerging insights
Crystal L. Mackall
National Cancer Institute, Bethesda, MD, United States
- Free
- audio + slides
- Some slides withheld
TIL therapy in the era of immune checkpoint blockade
John B.A.G. Haanen
Netherlands Cancer Inst., Amsterdam, Netherlands
- Free
- audio + slides
- Some slides withheld
Engineering T cells with introduced TCRs to effectively target tumors
Philip D Greenberg
Fred Hutchinson Cancer Res. Ctr. & Univ. of Washington, Seattle, WA, United States
- Free
- slides video
- audio + slides
- All slides included
Targeting driving genomic mutations in breast cancer
José Baselga
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Permission not
granted for presentation
Title to be announced
Jeffrey A. Engelman
Massachusetts General Hospital, Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Basket studies: Lessons learned and future directions
David Hyman
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Free
- audio + slides
- Some slides withheld
Dissecting colorectal cancer in multiple targetable subtypes
Josep Tabernero
Vall d'Hebron University Hospital, Barcelona, Spain
- Free
- slides video
- audio + slides
- All slides included
The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas
Howard Burris
Sarah Cannon Research Institute, Nashville, TN, United States
- Free
- slides video
- audio + slides
- All slides included
Introduction
Lee J. Helman
National Cancer Institute, Bethesda, MD, United States
- Free
- slides video
- audio + slides
- All slides included
National-scale cancer sequencing and treatment response data integration in The Netherlands
Edwin Cuppen
University Medical Center Utrecht, Utrecht, Netherlands
- Free
- slides video
- audio + slides
- All slides included
Assigning clinical meaning to genomic data for cancer precision medicine
Nikhil Wagle
Dana-Farber Cancer Institute, Brookline, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Delivering of the promise of personalized medicine
Gordon B. Mills
The University of Texas MD Anderson Cancer Center, Houston, TX, United States
- Free
- audio + slides
- Some slides withheld
Returning germline results to cancer patients
Sharon E. Plon
Baylor College of Medicine, Houston, TX, United States
- Free
- audio + slides
- Some slides withheld
Updates on engineered T cells as cancer therapies
Carl H. June
Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA, United States
- Permission not
granted for presentation
Impact of gut microbiota in cancer development and therapeutics
Laurence Zitvogel
Gustave Roussy Cancer Center, Villejuif, France
- Permission not
granted for presentation
Acquisition of resistance to anti-EGFR therapy drives genomic heterogeneity and lesion-specific responses in colorectal cancer
Giulia Siravegna
University of Torino - IRCCS Candiolo, Candiolo, Italy
- Free
- slides video
- audio + slides
- All slides included
Identification of a potent and selective chemical probe for exploring the role of CDK8/19 in cancer biology
Paul A. Clarke
Cancer Research UK Unit, The Institute of Cancer Research, London, United Kingdom
- Free
- audio + slides
- Some slides withheld
Novel ceritinib resistance mechanisms: new resistant mutation, fibroblast growth factor receptor 3 overexpression and cMET amplification-mediated ceritinib resistance
Ryohei Katayama
Japanese Foundation for Cancer Research, Tokyo, Japan
- Free
- audio + slides
- Some slides withheld
The radiology reading room of the future
Robert J. Gillies
Moffitt Cancer Center & Research Institute, Tampa, FL, United States
- Permission not
granted for presentation
Incorporating molecular imaging methods in early drug development
E. G. Elisabeth De Vries
Univ. Medical Ctr. Groningen, Groningen, Netherlands
- Free
- slides video
- audio + slides
- All slides included
Radiomics: The promise of imaging for personalized medicine
Hugo Aerts
Brigham & Women's Hospital, Boston, MA, United States